| Modality/agent | Target or mechanism | Key use-case | Selected 2024 efficacy/statistics | Key toxicities / implementation notes | Key 2024 sources with URL and pub month/year |
|---|---|---|---|---|---|
| Pediatric-inspired multi-agent chemotherapy (adult AYA/fit adults); e.g., pediatric-inspired regimens, Hyper-CVAD variants | Multi-agent cytotoxic therapy targeting proliferating lymphoblasts; often includes asparaginase, vincristine, steroids, anthracycline, methotrexate/6-MP phases | Standard frontline backbone for Ph-negative ALL in younger/fit adults; adapted intensity by age/fitness | ELN 2024: pediatric-based regimens are standard up to ~45–55 years and adult Ph-negative ALL CR rates are ~90% in many groups; expert review notes ~20% 5-year OS benefit in AYA with pediatric-inspired regimens vs traditional adult regimens (pqac-00000015, pqac-00000014) | Age/fitness constrained; asparaginase toxicity, infections, hepatic/pancreatic toxicity, thrombosis; obesity adversely affects OS in adults and may shape supportive-care intensity (pqac-00000014, pqac-00000043) | Gökbuget et al., *Blood* (May 2024) https://doi.org/10.1182/blood.2023023568 (pqac-00000015); Sebastian, *Clin Hematol Int* (May 2024) https://doi.org/10.46989/001c.117026 (pqac-00000014); Johnston et al., *Blood Adv* (Dec 2024) https://doi.org/10.1182/bloodadvances.2023011862 (pqac-00000043) |
| TKIs for Ph+ ALL (imatinib, dasatinib, ponatinib) | Inhibit BCR::ABL1 kinase signaling; ponatinib active against T315I and other resistant mutants | Frontline Ph+ ALL; often with reduced-intensity chemo or with blinatumomab; salvage/bridge contexts also used | Ponatinib review: PONALFIL post-induction CMR 47% rising to 71% in consolidation; 3-year OS 97%, EFS 70%; PhALLCON MRD-negative CR 34.4% with ponatinib vs 16.7% imatinib, and in age ≥60 years 40.0% vs 10.3%, median PFS 22.5 vs 8.3 months (pqac-00000020) | Cardiovascular/arterial occlusive risk with ponatinib; pancreatitis reported; TKI selection depends on mutation profile, age, comorbidities, CNS strategy, transplant plan (pqac-00000020, pqac-00000018) | Kantarjian et al., *Am J Hematol* (May 2024) https://doi.org/10.1002/ajh.27355 (pqac-00000020); Sebastian, *Clin Hematol Int* (May 2024) https://doi.org/10.46989/001c.117026 (pqac-00000018) |
| Blinatumomab | CD19xCD3 bispecific T-cell engager; redirects T cells to lyse CD19+ B-ALL cells | MRD-positive B-ALL; R/R B-ALL; increasingly frontline consolidation/low-intensity induction component in Ph-negative and Ph+ disease | Frontline Ph-negative phase 2 (reduced-dose chemo → blinatumomab): CRc 94% after 2 weeks blina, MRD-negative 86%; with up to 4 weeks, CR 100% and MRD-negative 89%; 1-year OS 97.1%, PFS 82.2% (NCT05557110) (pqac-00000023). Review/guideline: MRD response ~80% and hematologic relapse-free survival 61% in MRD-directed setting; survival benefit also emerging in MRD-negative frontline consolidation (pqac-00000013) | Continuous IV infusion standard; CRS and neurotoxicity/ICANS require monitoring; in Lu 2024 ICANS 14% (all grade 1), grade ≥3 CRS 9% (pqac-00000023) | Lu et al., *J Hematol Oncol* (Sep 2024) https://doi.org/10.1186/s13045-024-01597-8 (pqac-00000023); Stelljes, *Hematology* (Dec 2024) https://doi.org/10.1182/hematology.2024000531 (pqac-00000013); Gökbuget et al., *Blood* (May 2024) https://doi.org/10.1182/blood.2023023568 (pqac-00000015) |
| Inotuzumab ozogamicin | Anti-CD22 antibody-drug conjugate delivering calicheamicin | Approved for R/R CD22+ B-ALL; increasingly used in frontline low-intensity regimens in older/unfit adults; MRD eradication / bridge to HSCT / sequencing with CAR-T | 2024 reviews summarize strong efficacy in R/R disease and promising frontline combinations with low-intensity chemotherapy or blinatumomab; used to eliminate MRD and bridge to HSCT/CAR-T, but article excerpt does not provide one uniform 2024 pooled ORR/OS estimate across settings (pqac-00000016, pqac-00000012) | Key risk is veno-occlusive disease/sinusoidal obstruction syndrome, especially pre-HSCT; fractionated dosing and transplant timing matter (pqac-00000016) | Kantarjian et al., *Cancer* (Aug 2024) https://doi.org/10.1002/cncr.35505 (pqac-00000016); Gökbuget et al., *Blood* (May 2024) https://doi.org/10.1182/blood.2023023568 (pqac-00000012) |
| Chemo-free / near chemo-free TKI + blinatumomab for Ph+ ALL (e.g., ponatinib + blinatumomab; dasatinib + blinatumomab) | Dual targeting of BCR::ABL1 signaling plus CD19-directed T-cell cytotoxicity | Frontline Ph+ ALL; increasingly used to reduce/avoid conventional chemotherapy and sometimes HSCT | Ponatinib + blinatumomab (JCO 2024): CMR 83% overall (67% after course 1), NGS-MRD negativity 98%, only 2/60 underwent HSCT, 3-year OS 91%, EFS 77%, median follow-up 24 months (pqac-00000026, pqac-00000024). D-ALBA long-term: 4-year/approximately 53-month DFS 75.8%, OS 80.7%, early molecular responders had no events (pqac-00000020) | CNS relapse remains an issue in chemo-free Ph+ regimens; ponatinib vascular toxicities; blinatumomab CRS/neurotoxicity; transplant role becoming more selective (pqac-00000024, pqac-00000020) | Kantarjian et al., *J Clin Oncol* (Dec 2024) https://doi.org/10.1200/jco.24.00272 (pqac-00000026); Foà et al., *J Clin Oncol* (Mar 2024) https://doi.org/10.1200/jco.23.01075 (pqac-00000020) |
| CAR-T cell therapy (CD19-directed; pediatric and adult B-ALL) | Autologous engineered T cells targeting CD19 on B lymphoblasts | Standard for selected R/R B-ALL; bridge or alternative to HSCT; pediatric/young adult use especially established | 2024 treatment reviews state CAR-T is standard in R/R BCP-ALL and has demonstrated major efficacy, but the provided contexts here do not include a single 2024 trial with reportable ORR/OS figures for inclusion (pqac-00000013, pqac-00000016) | CRS, ICANS, prolonged cytopenias, hypogammaglobulinemia; manufacturing/access/logistics and disease burden at infusion are major real-world constraints; often sequenced with blinatumomab/inotuzumab/HSCT (pqac-00000016, pqac-00000013) | Stelljes, *Hematology* (Dec 2024) https://doi.org/10.1182/hematology.2024000531 (pqac-00000013); Kantarjian et al., *Cancer* (Aug 2024) https://doi.org/10.1002/cncr.35505 (pqac-00000016) |
| Allogeneic hematopoietic cell transplantation (allo-HCT) | Graft-versus-leukemia effect after myeloablative or reduced-intensity conditioning | Consolidation for high-risk disease, persistent/recurrent MRD, poor-risk genomics, or selected R/R patients in remission | ELN/expert reviews: MRD is central to transplant selection; poor MRD response supports SCT, whereas deeper MRD responses with TKI/blinatumomab regimens are reducing HSCT use in some Ph+ patients. In ponatinib+blinatumomab 2024 study, only 2 patients underwent HSCT despite 3-year OS 91% (pqac-00000028, pqac-00000024, pqac-00000015) | Transplant-related mortality, GVHD, infection, conditioning toxicity; pre-HSCT MRD level strongly predicts relapse; post-inotuzumab VOD/SOS risk requires mitigation (pqac-00000028, pqac-00000016) | Gökbuget et al., *Blood* (May 2024) https://doi.org/10.1182/blood.2023023568 (pqac-00000028); Kantarjian et al., *J Clin Oncol* (Dec 2024) https://doi.org/10.1200/jco.24.00272 (pqac-00000024) |
| MRD-directed therapy / response-adapted management | Uses highly sensitive residual leukemia detection (MFC, PCR, NGS) to escalate/de-escalate therapy and determine HSCT need | Cross-cutting strategy in frontline, MRD+, pre-/post-HSCT, and salvage settings | ELN 2024: threshold commonly 0.01% (10^-4); each log MRD increase worsens relapse risk; persistent/recurrent MRD should trigger therapy change; blinatumomab is the pivotal MRD-clearing agent. Review: MFC sensitivity ~10^-5; PCR/HTS up to 10^-6; key timepoints often 6–8 and 10–12 weeks (pqac-00000028, pqac-00000029) | Requires experienced reference labs; assay choice affects classification; marrow regeneration can confound flow; MRD does not capture extramedullary disease; low-level MRD may be intermediate-risk and still actionable (pqac-00000028, pqac-00000029) | Gökbuget et al., *Blood* (May 2024) https://doi.org/10.1182/blood.2023023568 (pqac-00000028); Yoon & Lee, *Korean J Intern Med* (Jan 2024) https://doi.org/10.3904/kjim.2023.407 (pqac-00000029) |


*Table: This table summarizes major modern treatment modalities for acute lymphoblastic leukemia, including frontline, MRD-directed, relapsed/refractory, and transplant strategies. It highlights 2024 efficacy data, implementation considerations, and key sources for rapid evidence-based comparison.*